Photobiomodulation Protocols in the Analgesia of Chemotherapy-induced Oral Mucositis in Children

Not Applicable

Recruiting

• Conditions: Mucositis Oral
• Interventions: Radiation: LLLT applied every other day; Radiation: LLLT applied daily

• Registration Number: NCT04596410
• Lead Sponsor: University Hospital, Toulouse

Brief Summary

Chemotherapy-induced oropharyngeal mucositis (OM) negatively impacts the quality of life of adult and pediatric patients by causing pain, dysphagia, dysgeusia and dysphonia.

Photobiomodulation (PBM) by low level laser therapy (LLLT), light therapy of low level of red and infrared wavelengths (630-1000 nm) has been recommended since 2014 in patients treated with high-dose chemotherapy for bone marrow transplantation. Available pediatric studies highlighted positive/promising results of PBM with excellent safety and no adverse effects. Nevertheless, a wide variety of application parameters is described in the literature, with no consensus guidelines.

Considering the lack of standardized protocol of photobiomodulation in the pediatric population as well as the burden and cost of a daily application, investigators have decided to conduct, for the first time in children of 3 years of age or older, a multicenter, randomized, double-blind, non-inferiority clinical trial to compare two PBM protocols with same PBM parameters, combining red and infrared wavelengths, but with different frequencies of laser application (daily versus every other day), in the treatment of chemotherapy-induced OM of WHO grade 2 or higher.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-09-04
• Study First Submitted QC: 2020-10-15
• Study First Posted: 2020-10-22
• Study Start: 2021-05-03
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-20
• Last Update Posted: 2023-09-22
• Primary Completion: 2024-01
• Study Completion: 2024-02

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 406

Inclusion Criteria

1. Male or female children aged ≥ 3 years and < 18 years.
2. Hospitalization in an oncology or hematology department in the participating centres.
3. Patients with oropharyngeal mucositis of grade 2 or higher (WHO grading system) related to cancer chemotherapy, including conditioning for Hematopoietic Stem Cell Transplantation (HSCT).
4. Written informed consent of both patient's holders of parental authority, and patient's assent when applicable.
5. Patients affiliated to a French Social Security insurance or equivalent social protection.
6. Absence of any physical or psychological disability that may interfere with the LLLT application.

Exclusion Criteria

1. Patients with a solid cancer lesion in the area of low-level laser application.
2. History of cervicofacial radiotherapy.
3. Application of low-level laser therapy for oral mucositis within 2 weeks prior to randomization.
4. Hyperthyroidism defined by TSH < 0.4 IU/mL at inclusion.
5. Patients susceptible to epilepsy seizure.
6. Patients with pacemaker.
7. Patients refusing to wear retinal goggles during low-level laser 1. Patients with a solid cancer lesion in the area of low-level laser application.
8. Patients protected by law (guardianship and safeguarding of justice).
9. Pregnant female patients as determined by positive serum pregnancy test at screening.
10. Lactating female patients who are actively breast feeding.
11. Participation in another clinical trial involving oral care.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
LLLT applied every other day	LLLT applied every other day	Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
LLLT applied daily	LLLT applied daily	Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every day

Primary Outcome Measures

Name	Time	Method
Session evaluation	Throught treatment period up to 1 month	Duration (in days) from the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM related pain at 2 consecutive measurements before the next scheduled PBM session (either active laser application or matching placebo application)

Secondary Outcome Measures

Name	Time	Method
OM occurrence	2 months	Occurrence of chemotherapy-induced OM of WHO grade 3 or 4 (deterioration of the clinical situation).
Feed evaluation	2 months	Occurrence of enteral feeding.
Pain change evaluation	From baseline to each day of PBM session	Change over time in WHO grade 2 or higher chemotherapy-induced OM related pain, as assessed by pain scales (HEDEN (Hétero Evaluation Douleur Enfant) mucositis scale (5 items ranging from 0 to 2) or VAS (ranging from 0 to 10)depending on patient's age category, and Children's International Mucositis Evaluation Scale (4 items ranging from 0 to 5) whatever patient's age category)
thyroid-stimulating hormone (TSH) evolution	From baseline to 2 months	TSH shift from baseline value classified according to the following three categories: "\< 0.4 IU/mL", "\[0.4 - 10\] IU/mL", "\> 10 IU/mL", to value at D14-31 after end of WHO grade 2 or higher chemotherapy-induced OM classified according to the same three categories.
Production costs evaluation	2 months	Production costs from the hospital perspective and efficacy (i.e. number of days after which a child has no longer mucositis related pain as described in the primary endpoint section) to build Incremental Cost-Effectiveness Ratio (ICER) comparing every other day LLLT application versus with daily LLLT application.
Health insurance evaluation	2 months	Costs of inpatient hospital stays from the French health insurance perspective.
OM duration evaluation	Throught treatment period up to 1 month	Duration (in days) of chemotherapy-induced OM of WHO grade 2 or higher between the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM at 2 consecutive measurements before the next scheduled PBM session (either every other day application or daily application).
Analgesic consumption	2 months	Duration (in days) of consumption of step 2 and step 3 analgesics during chemotherapy-induced OM of WHO grade 2 or higher.
PBM evaluation	Through treatment period up to 1 month	Duration (in days) from the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM related pain at 2 consecutive measurements before the next scheduled PBM session (either active laser application or matching placebo application) as evaluated, regardless of patient's age, with the ChIMES scale and use of step 3 analgesics.
Adverse events occurrence	2 months	Occurrence of adverse events reported according to descriptions and grading scale found in NCI CTCAE version 5.0.

Trial Locations

Locations (16)

University hospital of Toulouse; 🇫🇷 Toulouse, Occitanie, France

University hospital of Nancy; 🇫🇷 Nancy, France

University hospital of Poitiers; 🇫🇷 Poitiers, France

University hospital of Grenoble; 🇫🇷 Grenoble, France

Armand Trousseau Hospital; 🇫🇷 Paris, France

University hospital of Strasbourg; 🇫🇷 Strasbourg, France

University hospital of Lille; 🇫🇷 Lille, France

University hospital of Limoges; 🇫🇷 Limoges, France

Hôpital La Timone; 🇫🇷 Marseille, France

University Hospital of Tours; 🇫🇷 Tours, France

University hospital of Angers; 🇫🇷 Angers, France

University hospital of Besançon; 🇫🇷 Besançon, France

University Hospital of Nice; 🇫🇷 Nice, France

University hospital of Rouen; 🇫🇷 Rouen, France

University hospital of Saint-Etienne; 🇫🇷 Saint-Étienne, France

University hospital of Reims; 🇫🇷 Reims, France